Novartis plans to close a production facility in Wehr, Germany, by the end of 2028, a move that’s expected to eliminate 220 jobs, the Swiss pharma announced May 5.
The site, which makes solid oral dosage forms such as tablets and capsules for mostly established Novartis products, is no longer competitive, the company noted in its announcement. Novartis said it remains committed to Germany as a business location.
The pharma is investing 35 million euros (about $41 million) into a new production facility for radioligand therapies in Halle, Germany. The site will produce personalized cancer therapies for patients in Germany and should be operational in 2027, according to the announcement.